Navigation Links
HIV Patients May Be at Risk of Heart Problems When Taking Protease Inhibitor Drugs

A widely-used class of drugs that keep the HIV-virus infection from progressing to AIDS may cause serious and potentially lethal heart rhythm disturbances in some patients. The finding of a Mayo Clinic-led investigation appears in the current edition of The Lancet.

In collaboration with colleagues from the HIV Program of Hennepin County Medical Center, Minneapolis; the University of Minnesota, Minneapolis, and University of Wisconsin, Madison, the Mayo Clinic researchers made the discovery about a class of prescription drugs known as "HIV protease inhibitors." Drugs in this class go by the generic names of lopinavir, nelfinavir, indinavir, ritonavir and saquinavir. Brand names include Kaletra, Viracept, Crixivan, Norvir and Fortovase.

The researchers emphasize that the drugs' therapeutic benefits are still greater than the risk of heart problems linked to their use. They urge physicians to apply this new finding by following their patients more closely over the long term, and by looking specifically for heart rhythm irregularities in vulnerable individuals. They encourage physicians to be especially thorough when performing medical exams, and in taking patient histories to be alert for signs of heart rhythm disturbances.

Implications of the Findings

"In no way does it mean patients shouldn't receive protease inhibitors," says Andrew Badley, M.D., associate director of Mayo Clinic's Program in Translational Immunovirology and Biodefense. "It just means clinicians need to be aware of this new risk we've found, and act accordingly. Worldwide, tens of thousands of people are taking protease inhibitors, and the numbers who experience these unexpected side effects are very low -- much less than 1 percent."

Co-investigator Michael Ackerman, M.D., Ph.D. agrees that the benefits of the drugs far outweigh the risks. "Our findings should not jeopardize the availability of protease inhibitors because these drugs are too important for the successful treatment of HIV viral infection and control of AIDS. But hopefully our findings will save lives by alerting the physician to yet another side effect associated with this class of drug."

Dr. Ackerman is director of Mayo Clinic's Long QT Syndrome Clinic and Sudden Death Genomics Laboratory that specializes in various diseases and conditions that make a person vulnerable to sudden death by a ventricular arrhythmia.

There are several specific actions physicians can take to use this new information wisely, Drs. Ackerman and Badley say. The first is to screen by electrocardiogram for heart effects in vulnerable patients. The second is to be alert for multiple drug therapy situations, because certain drug-drug combinations could trigger the adverse heart side effects.

Background of the Discovery

Dr. Badley's research group earlier discovered that protease inhibitors affect "pore function" of "channels" in a specific cell type they were studying. Pore function in channels permits the exchange of biochemical signals within and between cells. After hearing of a case of heart rhythm disturbances in a patient taking protease inhibitors, the researchers looked for evidence of other patients with similar experiences. To do this, they used the U.S. Food and Drug Administration's voluntary drug side-effect database, the Adverse Event Reporting System. They identified 24 cases of heart rhythm disturbances -- all of which were associated with protease inhibitors.

They investigated the hypothesis that the widely-used protease inhibitors may, in fact, be linked to the development of heart rhythm problems through the mechanism of blocking a channel. Ultimately researchers from the University of Wisconsin led by Craig January, M.D., Ph.D., discovered that protease inhibitors do block these key channels.

"Our findings suggest that as a class, protease inhibitors may predispose individuals to QT interval problems or torsade de poi ntes," Dr. Badley says. Dr. Ackerman adds, "Long QT-adverse events are serious side effects in drugs, but with extra caution from physicians, this risk that we've identified can be managed, and that's the good news."

Collaborations

The research team also included Blake Anson, Ph.D., University of Wisconsin; Joel G.R. Weaver, M.D., Mayo Clinic and the University of Ottawa; Omobosola Akinsete, M.D., and Keith Henry, M.D., University of Minnesota and HIV Program of Hennepin County Medical Center, Minneapolis.


'"/>

Source:Mayo Clinic


Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Emory Eye Center Implants Its First Retinal Chips In Patients With Retinitis Pigmentosa
3. Implanted Devices Detect High-Risk Heart Failure Patients
4. Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments
5. Gene Signatures Predict Interferon Response For Multiple Sclerosis Patients
6. Bevacizumab Combined With Chemotherapy Improves Progression-Free Survival for Patients With Advanced Breast Cancer
7. Single-donor Islet Transplantation Procedure Shows Promise For Patients With Type 1 Diabetes
8. IMF Launches World’s First DNA Database for Myeloma Patients
9. Patients now surviving once-fatal immune disease
10. Patients and their doctors have different perceptions about HIV and its treatment
11. Patients to benefit from novel technology revolutionizing high-speed molecular imaging
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
Breaking Biology News(10 mins):
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
Breaking Biology Technology: